Myelodysplastic Syndrome Clinical Trial
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Summary
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
Eligibility Criteria
Inclusion Criteria:
Documented IDH1R132-mutant tumors
ECOG performance status ≤ 2
Exclusion Criteria:
Patients who have received prior treatment with a mutant-specific IDH1 inhibitor (with the exception of glioma patients)
Medical conditions that would prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures such as the presence of other clinically significant cardiac, respiratory, gastrointestinal, renal, hepatic or neurological disease.
Acute Promyelocytic Leukemia
Women who are pregnant or lactating
Other protocol-defined Inclusion/Exclusion may apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 13 Locations for this study
Boston Massachusetts, 02115, United States
New York New York, 10032, United States
Houston Texas, 77030, United States
Melbourne Victoria, 3004, Australia
Parkville Victoria, 3050, Australia
Leuven , 3000, Belgium
Toronto Ontario, M5G 2, Canada
Heidelberg , 69120, Germany
Jena , 07740, Germany
Koeln , 50937, Germany
Rotterdam , 3075 , Netherlands
Singapore , 16858, Singapore
Barcelona Catalunya, 08035, Spain
How clear is this clinincal trial information?